SPHK2 and lupus nephritis: Similar to the study by Snider et al. (81), which explored the inhibition of SphK2 for treating lupus nephritis, an increase in survival (p < 0.05) was observed; however, a decrease in anti-DNA autoantibodies and deposition of IgG was not observed (86).